Using the xenon-133 clearance technique for measurement of myocardial blood flow, it was shown that propanidid produced a large but transient increase in myocardial oxygen availability in the dog. With 5 mg/kg and 10 mg/kg, myocardial blood flow rose by 26% and 75% respectively, independent of any change in perfusion pressure, cardiac output or myocardial oxygen consumption. Cremophor-EL was found to have no effect on myocardial blood flow.
Since the introduction of propanidid into clinical practice, there has been considerable interest in its effect on the cardiovascular system. In most species, transient hypotension accompanied by a fall in cardiac output has been documented (Conway, Ellis and King, 1968; Sankawa, 1965; Clarke and Dundee, 1966) . In addition, a quinidine-like effect has been demonstrated in man (Johnstone and Barron, 1968) . Isolated instances of cardiovascular collapse have been reported recently in patients with, in some instances, evidence suggesting massive release of histamine or similar vasoactive substances (Gjessing, 1969; Bradburn, 1970; Johns, 1970; Larard, 1970; Miloschewsky and Cervenkova, 1970; Evans, 1971; Spreadbury and Marrett, 1971; Stovner and Endresen, 1971; Thornton, 1971; Jarvis, 1972; Turner, Keep and Bartholomaeus, 1972, etc.) .
The reported hypotensive action of propanidid has led some authors to advocate against its widespread use (Conway and Ellis, 1970) , whilst the antiarrhythmic properties have led others to imply a superiority over the barbiturates for induction of anaesthesia (Johnstone and Barron, 1968) . However, there are insufficient data to allow full assessment of the cardiovascular action of this agent.
The present study was undertaken to evaluate the effect of propanidid (Epontol) on the canine cardiovascular system in particular with regard to its effect on myocardial blood flow. Because attention has been directed to the so-called "inert" solvents (Editorial, 1971) propanidid solvent (polyoxyethylated castor oil or Cremophor-EL) was also studied.
METHODS
Anaesthesia was induced in ten healthy adult mongrel dogs with halothane and maintained with 0.5-1.0% trichloroethylene vaporized in a mixture of oxygen and nitrogen, the proportions of which were adjusted to maintain the arterial oxygen tension (Pao 2 ) at approximately 100 mm Hg. Reflex movements were prevented by the intermittent intramuscular administration of 50-mg doses of suxamethonium and ventilation was controlled with a Palmer pump, the tidal volume of which was adjusted to maintain an arterial carbon dioxide tension (Paco 2 ) in the range 35-45 mm Hg. Catheters were inserted into the right atrium, descending aorta, coronary sinus and left coronary artery. "Mixed venous", arterial and coronary sinus blood gases were measured using Radiometer electrodes (McDowall, Ledingham and Tindal, 1968) . Systemic and right atrial pressures were measured using Elema-Schonander transducers recording on a Mingograf 81 ink jet recorder. Standard lead II of the electrocardiogram was recorded and used for calculation of heart rate. Cardiac output was determined by the dye dilution method using indocyanine green and a Water's cuvette densitometer (XP-302). Total body consumption was calculated as the product of cardiac output and arterio -"mixed venous" oxygen content difference. Myocardial blood flow and myocardial oxygen consumption were determined by the inert gas clearance technique as described in previous communcations (Vance, Brown and Smith, 1973; Ledingham et al., 1971) .
Following induction of anaesthesia and catheterization of appropriate vessels, at least 1 hour was allowed to elapse prior to commencement of measurements. After a baseline had been established, propanidid 5 mg/kg was injected through the right aerial catheter slowly over a 10-15-second period with continuous recording of arterial blood pressure. Two complete sets of measurements were then made as rapidly as possible. Owing to the time involved in measuring myocardial blood flow with the inert gas technique, measurements were usually obtained at 0.5 and 3-4 min after completion of injection. A third set of measurements was made 15 min after injection.
In six of the ten animals, the effect of a larger dose of propanidid (10 mg/kg) was also assessed. In five animals, the effect of the propanidid solvent (Cremophor-EL) was examined. The volume of Cremophor (0.1 ml/kg) was equivalent to a 5 mg/kg injection of propanidid. Where different doses or substances were used in the same animal, the order of administration was randomized and at least 30 min elapsed between successive injections. In four animals, delayed hypotension occurred following the first injection of propanidid or solvent and, in these instances, 1-H hours was allowed to elapse for a new baseline to be established. Significance of the difference between group means was assessed using the unpaired Student f-test.
RESULTS
The haemodynamic and blood-gas data in dogs before and after injection of propanidid 5 mg/kg are shown in table I. Results are expressed as the mean ± the standard error of the mean (SEM). At 0.5 min following the injection of this dosage of propanidid, there was no significant change in mean blood pres- This was accompanied by a rise in myocardial oxygen availability of 27% (P<0.05). In the face of an unchanged oxygen consumption by the myocardium, the rise in oxygen availability was accompanied by a fall in oxygen extraction from 44% to 36% (P<0.05) and a non-significant rise in coronary sinus Po 3 from 35.5 ±2.4 to 40.2±2 mm Hg.
At 3-4 min and 15 min after injection of propanidid, none of the measurements was significantly different from the preinjection values.
Results obtained following the injection of propanidid 10 mg/kg are shown in table II. At i min postinjection, heart rate had increased by 11% from 207 +12 to 229 +13 beats/min, although this difference was not significant. Mean arterial blood pressure, cardiac output and right atrial pressures were unchanged. Myocardial blood flow rose by 75% from 88.5 ±11.8 to 155 ±18.4 ml.min-UOOg-1 (P<0.05). There was no change in myocardial oxygen consumption and the 70% increase in myocardial oxygen availability was accompanied by a 56% fall in oxygen extraction.
These early transient effects of propanidid on myocardial blood flow were not seen with the drug solvent (table HI). At 30 sec following injection of Cremophor, there was no change in any of the systemic or myocardial blood-gas and haemodynamic measurements. However, by 15 min postinjection, cardiac output had fallen by 29% (P<0.05). There was no significant change in myocardial oxygen consumption or myocardial blood flow.
In four animals, delayed hypotension occurred in association with gross flushing of the skin of the abdomen following the first injection of either propanidid or Cremophor. In the two dogs in which propanidid was used as the first test injection of the experiment, mean blood pressure fell from 120 and 185 to 40 and 105 mm Hg after 35 and 31 min respectively. With the solvent, the mean arterial pressure fell from 140 and 160 to 88 and 55 mm Hg after 35 and 20 min respectively. One to H hours elapsed before recovery was complete.
The change in myocardial blood flow produced by propanidid occurred consistently with repeated injections in the same dog. Figure 1 illustrates an experiment showing the effect of two injections of propanidid and two injections of Cremophor on mean systemic blood pressure, myocardial blood flow and myocardial oxygen consumption. Thirty seconds after the first injection of propanidid there was a marked rise in myocardial blood flow but no change in blood pressure and after the second injection a rise of similar magnitude. After the first injection of solvent in this particular animal, there was a small fall in flow whereas little change occurred with the second injection. Pure propanidid, i.e. the active substance which was not dissolved in any solvent, was tested on a few occasions and found to produce a rise in myocardial blood flow ( fig. 2) . In this experiment, propanidid 5 mg/kg produced a 43 % increase in flow whilst a dose of 10 mg/kg produced an 84% rise. Pure propanidid produced a more sustained increase in flow of 24% while the solvent again had little effect.
DISCUSSION
Previous studies of the cardiovascular effects of propanidid have reported arterial hypotension of brief duration. Sankawa (1965) found hypotension lasting approximately 2 min with doses of 20-25 mg/kg whilst Conway, Ellis and King (1968) found a reduction in systolic blood pressure of 34-47% which lasted 1-2 min following doses of 10-20 mg/kg. In many human studies, transient hypotension has also been reported (Conway and Ellis, 1970) . In the present study, very slight and unremarkable transient hypotension was seen within seconds following injection of both 5 and 10 mg/kg doses but by the time a full set of measurements was made at 30 sec after injection, the blood pressure was unchanged from the preinjection control values. However, in 40% of the dogs, following the first injection of either propanidid or Cremophor, there was a delayed hypotension which started some 15-20 min after injection and lasted 30-90 min, and was associated with gross flushing of the skin of the abdomen. A similar "secondary hypotension" occurring only after the first injection of propanidid was described by Conway, Ellis and King (1967) . This was evident 4 min after injection and recovery was present by 60 min. It seems likely that the differences between the hypotensive effect of propanidid reported by Conway and associates and those reported here may be attributed to the smaller dose of propanidid and to the rather slow rate of injection in our study. Furthermore, Conway and associates showed that the duration of hypotension was approximately 60 sec following the injection of propanidid. Owing to the time involved between commencing each injection and measurement of myocardial blood flow (40-50 sec) in our study, the recorded blood pressure was unchanged from the preinjection value.
It is pertinent to note that the calculation of myocardial blood flow by the xenon clearance technique assumes that the washout of xenon from the myocardium follows a mono-exponential course. Whilst this is correct in the steady state, during a phase of rapid change in flow this may not be so. Our analysis of flow was made on a washout period of 35 sec and it is likely that changes in flow were occurring during the 0.5-min measurement. However, transformation on to semilogarithmic paper did not reveal a significant deviation from linearity and we feel justified in regarding the changes we measured as accurately reflecting the qualitative changes occurring in myocardial blood flow.
We have shown that propanidid but not the solvent produced a transient rise in myocardial Wood flow of 26% and 75% with the low and high doses respectively. This was unrelated to significant changes in heart rate, perfusion pressure and cardiac output and there was no change in myocardial oxygen consumption or arterial oxygen tension or carbon dioxide tension. It seems reasonable to assert, therefore, that the effect on the myocardial vascular resistance was due to a direct action on the myocardial blood vessels.
The question arises as to whether this effect was mediated via the release of histamine by propanidid. There are several reasons for attributing little importance to histamine release. (a) The time-course of events. The effect of propanidid was extremely rapid and lasted no longer than 2 min. The delayed hypotension and gradual flushing of the skin following the first injection of either propanidid or solvent are changes more typical of the release of vasoactive substances (Lorenz et al., 1972) . (b) Cremophor, and not propanidid, has been shown to release histamine in the dog (Lorenz et aL, 1972; Wirth and Hoffmeister, 1965 ) and yet, in this study, the solvent was without effect on myocardial blood flow. (c) The response to repeated injections of the same dose of propanidid in the same animal was fairly constant. Although it is difficult to extrapolate from this study to the clinical situation, there is no evidence here which would mitigate against the use of propanidid in patients with or without myocardial disease. However, we were dealing with a preparation which was already anaesthetized and this is not comparable to giving induction agents to a conscious animni In the dog, induction of anaesthesia with propanidid requires a dose of the order of 20 mg/kg and we have used 5 mg/kg which is comparable to that for man Previous workers have feared the reported hypotensive effect of the larger doses of propanidid with the implication that perfusion pressure of the coronary circulation is impaired. This study clearly shows that in the dog the drug produces a very large but transient increase in myocardial oxygen availability.
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